Drug Sales Trends for GIANVI


Annual Sales Revenues and Units Sold for GIANVI
| Drug Name | Revenues (USD) | Units | Year |
|---|---|---|---|
| GIANVI | ⤷ Start Trial | ⤷ Start Trial | 2022 |
| GIANVI | ⤷ Start Trial | ⤷ Start Trial | 2021 |
| GIANVI | ⤷ Start Trial | ⤷ Start Trial | 2020 |
| GIANVI | ⤷ Start Trial | ⤷ Start Trial | 2019 |
| GIANVI | ⤷ Start Trial | ⤷ Start Trial | 2018 |
| GIANVI | ⤷ Start Trial | ⤷ Start Trial | 2017 |
| >Drug Name | >Revenues (USD) | >Units | >Year |
Gianvi Market Analysis, Sales History, Patent Status, and Revenue Projections
Gianvi is Teva Pharmaceuticals' branded version of drospirenone 3 mg and ethinyl estradiol 0.02 mg tablets, the same active-ingredient combination marketed as Yaz by Bayer. Gianvi entered the U.S. market as a lower-priced alternative after patent litigation and regulatory review. Its commercial opportunity was concentrated in the U.S. oral contraceptive market and declined rapidly as multiple generic manufacturers entered.
Standalone Gianvi sales are not publicly reported in Teva's financial disclosures. Current revenue attributable to the Gianvi brand is likely negligible. The commercially relevant market is the broader U.S. market for drospirenone/ethinyl estradiol tablets, where pricing, payer coverage, pharmacy substitution and competition from generic manufacturers determine revenue.
What is Gianvi and how large is its market?
Gianvi contains 3 mg of drospirenone and 0.02 mg of ethinyl estradiol in a 28-tablet regimen. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic properties. The product is indicated for pregnancy prevention and, under specified conditions, treatment of moderate acne and premenstrual dysphoric disorder. The product label includes the cardiovascular, thromboembolic and hyperkalemia warnings associated with combined hormonal contraceptives and drospirenone-containing products. [1]
The addressable market has three segments:
| Market segment | Commercial relevance to Gianvi |
|---|---|
| U.S. drospirenone/ethinyl estradiol tablets | Core market |
| All combined oral contraceptives | Competitive substitute market |
| Acne and premenstrual dysphoric disorder treatment | Secondary demand driver |
Gianvi competes with Yaz, generic drospirenone/ethinyl estradiol products, Nikki, Loryna, Vestura and other equivalent or near-equivalent oral contraceptives. Most prescriptions are dispensed through pharmacy benefit plans, which favor generic substitution.
When did Gianvi launch and how did sales develop?
Gianvi received U.S. Food and Drug Administration approval in 2010. Teva positioned it as an authorized alternative to Yaz and entered after litigation involving Bayer's Yaz patent estate. [1, 2]
The commercial trajectory had four phases:
| Period | Market event | Expected impact on Gianvi |
|---|---|---|
| 2010-2011 | Initial launch and limited competition | Rapid prescription growth |
| 2012-2014 | Additional generic entrants | Price and share erosion |
| 2015-2019 | Mature generic market | Low unit economics |
| 2020 onward | Loss of remaining key patent barriers and broad substitution | Minimal branded value |
Gianvi did not develop the durable pricing power associated with a differentiated new molecular entity. Its active ingredients were already established, and the principal commercial advantage was timing of entry and brand recognition.
Teva does not generally report Gianvi as a separate revenue line. The product's sales would have been included in broader generic or pharmaceutical product categories. As a result, public filings do not provide a defensible standalone annual-sales series for Gianvi. [3]
What is the current FDA and Orange Book status of Gianvi?
Gianvi was approved under a separate new drug application rather than as a conventional ANDA generic product. The reference product for the active-ingredient combination was Yaz, marketed by Bayer.
The FDA Orange Book is relevant for three reasons:
- It identifies the approved reference products and applicable patent information.
- It records whether listed patents remain relevant to abbreviated applications.
- It helps determine whether a Paragraph IV certification could create litigation exposure.
Gianvi's initial regulatory value was tied to its ability to enter the market before or alongside later ANDA products. Once multiple ANDA manufacturers received approval for drospirenone/ethinyl estradiol tablets, the brand's regulatory distinction had little commercial significance.
The FDA label identifies Gianvi as a prescription oral contraceptive containing drospirenone and ethinyl estradiol. [1] Product availability has changed over time, and current pharmacy listings may show generic equivalents rather than the Gianvi brand.
What patents protected Gianvi and Yaz?
The primary patent dispute involved Bayer's U.S. Patent No. 6,787,531, which covered aspects of drospirenone-containing pharmaceutical compositions. The patent was listed in connection with Yaz and became the subject of ANDA litigation involving generic applicants, including Barr Laboratories and Teva-related entities. [2, 4]
The patent estate did not create a long-term barrier to competition because:
- The patent was challenged through Paragraph IV certifications.
- Courts addressed validity and infringement issues before final market exclusivity expired.
- Multiple generic manufacturers entered after the relevant patent barriers fell.
- Formulation and method-of-use claims were less commercially durable than broad composition claims.
The practical exclusivity timeline was:
| Event | Approximate timing |
|---|---|
| Yaz U.S. approval | 2006 |
| Key Bayer patent expiration period | 2020, including applicable extensions and pediatric adjustments |
| Gianvi approval and launch | 2010 |
| Broad generic competition | 2010s |
| Mature multisource market | Late 2010s onward |
Exact Orange Book patent status should be assessed by historical edition because listed patents, pediatric exclusivity and product status can change over time. The commercial conclusion remains consistent: Gianvi does not have a meaningful surviving patent moat.
How many competitors challenge Gianvi in the U.S.?
Competition is extensive. Products containing the same active ingredients have been marketed by several manufacturers, including Teva, Mylan or Viatris, Lupin, Glenmark, Amneal, Sandoz and other generic suppliers over time.
The principal competitive factors are:
- Wholesale acquisition cost
- Medicaid and commercial formulary placement
- Pharmacy substitution
- Manufacturer supply reliability
- 28-tablet packaging
- Availability of branded or authorized-generic versions
- Contracting with wholesalers and pharmacy benefit managers
Generic contraceptive products tend to experience rapid price compression when several approved suppliers are available. A product may retain prescription volume while losing most of its revenue because reimbursement shifts toward the lowest-cost supplier.
What are the sales projections for Gianvi?
A standalone Gianvi brand projection should be separated from the projection for the entire drospirenone/ethinyl estradiol market.
Gianvi brand revenue projection
| Year | Base-case estimated Gianvi brand revenue | Commercial interpretation |
|---|---|---|
| 2024 | $0-$2 million | Limited or discontinued branded sales |
| 2025 | $0-$1.5 million | Residual prescriptions, if available |
| 2026 | $0-$1 million | Further substitution |
| 2027 | $0-$1 million | No material recovery expected |
| 2028 | $0-$1 million | Brand value remains immaterial |
These are market-model estimates, not reported Teva guidance. The projection assumes that Gianvi remains commercially subordinate to generic drospirenone/ethinyl estradiol products and does not regain preferred formulary status.
Broader drospirenone/ethinyl estradiol market projection
The broader market should remain commercially active because the product has established use in contraception, acne management and premenstrual dysphoric disorder. Revenue growth is likely to be driven by prescription volume rather than price.
| Scenario | 2025-2028 unit trend | Net-price trend | Market revenue outlook |
|---|---|---|---|
| Low case | Flat to declining | Down 8%-12% annually | Declining |
| Base case | 1%-3% annual growth | Down 4%-8% annually | Flat to moderately declining |
| High case | 3%-5% annual growth | Down 2%-5% annually | Flat to modestly growing |
The base case assumes continued generic substitution, stable demand for combined oral contraceptives and no major safety-driven withdrawal. Under this model, market revenue declines despite stable or slightly higher prescription volume.
What generic launch risks exist for Gianvi?
Generic launch risk is no longer a future event for Gianvi. It is the central reason the brand has limited commercial value.
The main risks are:
- Continued entry by approved ANDA manufacturers
- Contracting pressure from pharmacy benefit managers
- Price reductions by manufacturers seeking volume
- Product shortages that shift share temporarily among suppliers
- Brand discontinuation or limited distribution
- Substitution by newer oral contraceptive products and long-acting reversible contraceptives
Generic manufacturers can compete without duplicating Gianvi's brand investment. FDA-approved equivalents generally receive automatic pharmacy substitution where state law and payer policy permit.
What formulation and method-of-use protections remain?
Gianvi's formulation is not commercially differentiated. The tablet contains the same active ingredients and strengths as Yaz and competing equivalents.
Potentially relevant protection categories historically included:
- Drospirenone and ethinyl estradiol compositions
- Specific tablet formulations
- Packaging and dosing regimens
- Treatment of acne
- Treatment of premenstrual dysphoric disorder
- Contraceptive methods using the combination
These claims may have supported litigation or product differentiation during the early lifecycle. They do not provide a significant current barrier because equivalent products are widely available and the principal patents have expired or lost practical exclusivity.
Which companies are positioned to capture the market?
The market is fragmented among generic suppliers. Teva retains manufacturing, distribution and regulatory capabilities, but those capabilities do not ensure brand-level pricing.
| Company type | Competitive position |
|---|---|
| Teva | Historical Gianvi sponsor and major generic supplier |
| Viatris and other large generic companies | Scale, payer contracting and broad pharmacy access |
| Specialty generic manufacturers | Lower-cost supply and selective channel participation |
| Bayer | Yaz brand legacy, but limited post-patent pricing power |
| Digital and reproductive-health platforms | Demand generation and prescription access rather than manufacturing |
The strongest commercial position belongs to suppliers with reliable inventory, low cost of goods and favorable wholesaler contracts. Patent ownership is no longer the primary competitive advantage.
How does Gianvi compare with Yaz and other contraceptives?
| Attribute | Gianvi | Yaz | Generic equivalents | Long-acting contraceptives |
|---|---|---|---|---|
| Active ingredients | Drospirenone/EE | Drospirenone/EE | Drospirenone/EE | Different products |
| Brand premium | Low or absent | Historically higher | Minimal | Product-specific |
| Patent protection | Expired or commercially weak | Expired or commercially weak | No meaningful brand moat | Depends on product |
| Formulary position | Usually generic | Often nonpreferred | Frequently preferred | Varies |
| Revenue outlook | Negligible brand revenue | Limited brand revenue | Volume-driven | Potentially stronger pricing |
Gianvi's closest competitors are generic equivalents, not newer contraceptive mechanisms. The principal market threat comes from substitution within the same active-ingredient class and from long-acting methods such as intrauterine systems and implants.
What is the investment and licensing outlook for Gianvi?
Gianvi has limited licensing value as a standalone brand. The product lacks:
- A live composition patent moat
- A differentiated delivery system
- A protected manufacturing process with clear market impact
- A publicly disclosed royalty stream
- Material standalone revenue disclosure
Potential value may exist in a broader portfolio transaction involving Teva's contraceptive products, manufacturing capacity or generic regulatory dossiers. A transaction based solely on Gianvi would likely be justified by residual cash flow, channel access or supply capability rather than intellectual property.
Key Takeaways
- Gianvi is Teva's drospirenone/ethinyl estradiol product and a lower-priced alternative to Yaz.
- The product launched in 2010 and entered a market that quickly developed broad generic competition.
- Standalone Gianvi sales are not publicly disclosed.
- Current Gianvi brand revenue is likely negligible, with a modeled 2025 revenue range of $0 to $1.5 million.
- The broader drospirenone/ethinyl estradiol market is expected to remain prescription-stable but price-deflationary.
- The principal patent barriers associated with Yaz and Gianvi no longer provide meaningful commercial exclusivity.
- Future value depends on manufacturing economics, distribution and payer access, not patent protection.
FAQs About Gianvi Sales, Patents and Market Competition
Is Gianvi still sold in the United States?
Gianvi's commercial availability has declined substantially as generic drospirenone/ethinyl estradiol products replaced the brand. Pharmacy availability may vary by wholesaler and payer.
Is Gianvi the same as Yaz?
Gianvi and Yaz contain the same strengths of drospirenone and ethinyl estradiol. They are different branded products but are therapeutically comparable for approved uses.
Does Gianvi have patent protection?
Gianvi does not have a commercially meaningful surviving patent barrier. Historical protection was connected to patents covering drospirenone-containing compositions, formulations and related uses.
What is the generic name for Gianvi?
The generic name is drospirenone and ethinyl estradiol tablets, containing 3 mg of drospirenone and 0.02 mg of ethinyl estradiol.
Can Gianvi regain market share?
A material recovery would require a new commercial strategy, such as preferred payer placement, renewed brand promotion or a supply disruption affecting generic competitors. Without those conditions, generic substitution will continue to limit brand revenue.
References
- U.S. Food and Drug Administration. (2010). Gianvi prescribing information: Drospirenone and ethinyl estradiol tablets.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Teva Pharmaceutical Industries Ltd. (2010-2024). Annual reports and Form 20-F filings.
- Bayer Healthcare Pharmaceuticals, Inc. v. Barr Laboratories, Inc., 575 F.3d 1341 (Fed. Cir. 2009).
More… ↓
